Accelerating Approval Times for New Drugs in the US

The Regulatory Affairs Journal

首页> 外文期刊>The regulatory affairs journal: Pharma >Accelerating Approval Times for New Drugs in the US

【24h】

Accelerating Approval Times for New Drugs in the US

机译：加快美国新药批准时间

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In the past two decades, review times for drugs approved by the US Food and Drug Administration (FDA) have dropped appreciably. Estimates of the exact magnitude of the decline differ, depending on which drugs are included, how exactly times are measured, and how statistical averages are calculated. Yet no serious analyst denies that the decline occurred or that it was significant.

机译：在过去的二十年中，美国食品药品监督管理局（FDA）批准的药品审查时间已明显减少。下降的确切幅度的估计值会有所不同，具体取决于所包括的药物，如何精确测量时间以及如何计算统计平均值。然而，没有认真的分析师否认下降是发生了还是很大。

著录项

来源
《The regulatory affairs journal: Pharma》 |2004年第6期|共8页
作者
The Regulatory Affairs Journal;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Accelerating Approval Times for New Drugs in the US [J] . The Regulatory Affairs Journal The regulatory affairs journal: Pharma . 2004,第6期

机译：加快美国新药批准时间
2. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs [J] . Kraus V. B., Simon L. S., Katz J. N., Osteoarthritis and cartilage . 2019,第4期

机译：根据代理终点的批准和促销FDA加速审批法规的批准批准的批准研究设计，用于修饰骨关节炎药物的加速批准规定
3. The Role of Patient Participation in Drug Approvals: Lessons from the Accelerated Approval of Eteplirsen [J] . Edwards Kyle T. Food and Drug Law Journal . 2017,第3期

机译：患者参与毒品批准的作用：来自ETEPLIRSEN加速批准的课程
4. Investigating the Food and Drug Administration (FDA) Biotherapeutics Review and Approval Process: A Scoping Review [C] . Samuel A. Bonet, Farzan Sasangohar, Mark Lawley Human Factors and Ergonomics Society annual meeting . 2018

机译：调查食品和药物管理局（FDA）生物治疗审查和审批过程：审查审查
5. Pharmaceutical corporate mission statement components and their relationship to drug approval time [D] . Cooper, Lisa D. 2014

机译：制药企业使命陈述成分及其与药物批准时间的关系
6. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals [O] . Austin Lammers, Ruibin Wang, Jeremy Cetnar, 2017

机译：从美国食品药品监督管理局批准到癌症药物数据发布的时间：首次批准与后续批准的比较
7. Characteristics of pre-approval and post-approval studies for drugs granted accelerated approval by the US food and drug administration [O] . Naci, Huseyin, Smalley, Katelyn R., Kesselheim, Aaron S. 2017

机译：美国食品和药物管理局加速批准的药品批准前和批准后研究的特征
8. New Animal Drug Applications: An Analysis of Approval Rates, Approval Times, and Deficiencies from 1972 through 1981 [R] . Prunella, P. , Carnevale, R. , Gardner, P. , 1983

机译：新动物药物应用：对1972年至1981年的批准率，批准时间和缺陷的分析

Accelerating Approval Times for New Drugs in the US

摘要

著录项

相似文献

相关主题

期刊订阅